Related Experiment Videos
Dihydrexidine--the first full dopamine D1 receptor agonist
Peter Salmi1, Ruben Isacson, Björn Kull
1Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden. peter.salmi@cgb.ki.se.
CNS Drug Reviews
|October 20, 2004
Summary
Dihydrexidine, a potent dopamine D(1) receptor agonist, shows promise for Parkinson's disease and CNS disorders. However, its clinical use is limited by side effects, necessitating further research into dopamine D(1) receptor agonists.
Area of Science:
- Neuroscience
- Pharmacology
- Medicinal Chemistry
Background:
- The precise function of dopamine D(1) receptors remains debated, partly due to limitations of early agonists like SKF 38393.
- The development of selective and fully efficacious dopamine D(1) receptor agonists was crucial for advancing research and exploring clinical applications.
Purpose of the Study:
- To review the pharmacology of dihydrexidine, a key dopamine D(1) receptor agonist.
- To discuss the potential clinical utility of dopamine D(1) receptor agonists in central nervous system disorders.
Main Methods:
- Review of scientific literature on dihydrexidine and dopamine D(1) receptor agonists.
- Analysis of pharmacological data, including receptor binding and cyclic AMP stimulation.
- Evaluation of preclinical efficacy in animal models of neurological disorders.
Main Results:
- Dihydrexidine, a phenanthridine agonist, exhibits full efficacy at dopamine D(1) receptors, surpassing the partial agonist SKF 38393.
- Dihydrexidine demonstrated significant antiparkinsonian activity in primate models, suggesting therapeutic potential.
- Despite its efficacy, dihydrexidine's pharmacokinetic limitations and adverse effects hinder human application.
Conclusions:
- The intrinsic efficacy of dopamine D(1) receptor agonists appears critical for their therapeutic potential in Parkinson's disease and other CNS disorders.
- While dihydrexidine has been a valuable research tool, its limitations highlight the need for developing improved dopamine D(1) receptor agonists for clinical use.